Malignancies of B-cells have been treated using a variety of strategies to interfere with malignant cell survival pathways. Recent approaches include the development of targeted therapies in cancer treatment, particularly that of the class of targeted protein degradation (TPD), which is conceptually distinct from conventional enzyme inhibition by creating degradation of the targeted protein.
BGB-16673 (Tacabrutideg) is a novel, investigational Bruton's tyrosine kinase (BTK) protein degrader being studied in patients with B-cell malignancies, including those whose diseases have relapsed or are refractory following treatment with covalent BTK inhibitors. Early-phase studies are assessing its safety, efficacy, and potential treatment uses in patients with B-cell malignancies.
